
    
      The main period of the study consists of a maximum of 21-day screening phase, then first 2
      treatment cycles with cabazitaxel. End of main period will be Cycle 3 or 30 days after last
      dose if patient discontinues study after 1 or 2 treatment cycles. The duration for a patient
      for the main period of the study will be about 9 to 10 weeks (screening, 2 cycles).

      After Cycle 2, patients will have the option to continue to receive cabazitaxel and should be
      followed for safety reporting until 30 days after the last dose of cabazitaxel.
    
  